Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR)

This study has been completed.
Sponsor:
Information provided by:
Cordis Corporation
ClinicalTrials.gov Identifier:
NCT00231257
First received: September 30, 2005
Last updated: November 17, 2009
Last verified: November 2009
  Purpose

The main objective of this study is to demonstrate the superiority or non-inferiority of the sirolimus-eluting Bx VELOCITY® stent compared to intravascular brachytherapy in patients with in-stent restenotic native coronary artery lesions.


Condition Intervention Phase
In-Stent Restenosis
Device: Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
Procedure: Brachytherapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized Study of the Sirolimus-Eluting Bx VELOCITY® BALLOON Expandable Stent vs. Intravascular Brachytherapy in the Treatment of Patients With In-Stent Restenotic Coronary Artery Lesions

Resource links provided by NLM:


Further study details as provided by Cordis Corporation:

Primary Outcome Measures:
  • Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization at 9 months post-procedure. [ Time Frame: 9 months post-procedure. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Angiographic in-lesion and in-stent binary restenosis (³ 50% diameter stenosis) at 6 months post-procedure (by QCA). [ Time Frame: 6 months post-procedure ] [ Designated as safety issue: Yes ]
  • Post-procedure and six-month in-stent and in-lesion percent diameter stenosis (%DS) and late loss at 6 months post-procedure (by QCA) - [analysis at 6 months chosen so that results from the GAMMA Trial can be used]. [ Time Frame: 6 months post-procedure ] [ Designated as safety issue: Yes ]
  • Post-procedure and six-month in-stent and in-lesion minimum lumen diameter (MLD) (by QCA). [ Time Frame: Post-procedure and at six-month ] [ Designated as safety issue: Yes ]
  • Target lesion revascularization (TLR) at 6 and 9 months post-procedure. [ Time Frame: 6 and 9 months post-procedure ] [ Designated as safety issue: Yes ]
  • Target vessel revascularization (TVR) at 6 and 9 months post-procedure. [ Time Frame: 6 and 9 months post-procedure ] [ Designated as safety issue: Yes ]
  • Composite of Major Adverse Cardiac Events (MACE) defined as death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization at 30 days and 6, 9, and 12-months, and 2, 3, 4, and 5 years post-proce [ Time Frame: 30 days and 6, 9, and 12-months, and 2, 3, 4, and 5 years post-procedure ] [ Designated as safety issue: Yes ]
  • Stent lumen and stent obstruction volume by intravascular ultrasound (IVUS) at post-procedure and six months in a subset of patients conducted at 5-7 investigational centers. [ Time Frame: post-procedure and six months ] [ Designated as safety issue: Yes ]
  • Cost associated with the index hospitalization, length of stay, and repeat hospitalizations during the 12 mo post-procedure follow-up. [ Time Frame: 12 mo post-procedure ] [ Designated as safety issue: No ]
  • Rate of late thrombosis [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

Enrollment: 384
Study Start Date: February 2003
Study Completion Date: September 2009
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Cypher Bx Velocity
Device: Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
Active Comparator: 2
Brachytherapy
Procedure: Brachytherapy
Brachytherapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. The patient has an in-stent restenosis of > 50% (by subjective angiographic determination of the minimal luminal diameter compared to the distal reference diameter) within a native coronary artery which has previously undergone stent placement ( 4 weeks). Lesions must meet ISR Classification I-III.

    2. The patient has a history, signs of, or laboratory studies that suggest coronary ischemia attributable to the target stenosis. The diagnosis of angina pectoris is defined by Canadian Cardiovascular Society Classification (CCS I, II, III, or IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR patients with documented silent ischemia;

    3. The study target lesion must be located in an in-stent restenotic native coronary artery measuring > 2.75mm and 3.5mm in diameter and > 15mm and 40mm in length to allow treatment with a maximum of three 18mm stents. The target lesion must have undergone coronary interventional treatment > 4 weeks previously. Patients with one or more prior percutaneous coronary interventions at the target lesion are acceptable candidates.

    4. The vessel 1cm distal to the target lesion is > 2.5mm in diameter;

    5. Ejection Fraction must be > 40%;

    6. The study target lesion cannot be located in a vessel containing a second lesion requiring treatment at the time of the procedure.

    7. Male or non-pregnant female patients > 18 years of age inclusive. NOTE: Females of child-bearing potential must have a negative pregnancy test (urine or serum) prior to enrollment and must use birth control for 6 months.

Exclusion Criteria:

  1. The study target lesion has definite or possible thrombus present by angiographic criteria.
  2. The patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK > 2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remain above normal at the time of treatment.
  3. Impaired renal function (Serum creatinine > 2.0mg/dl);
  4. The patient has unstable angina classified as Braunwald III B or C, or is having peri infarction angina.
  5. The left ventricular ejection fraction is < 40%.
  6. The target vessel has previously sustained a perforation.
  7. Totally occluded vessel (TIMI 0 level);
  8. Prior stent within 5mm of target lesion;
  9. There is a total occlusion of the restenosed-stent (ISR Classification IV) prior to the interventional procedure.
  10. Has an ostial target lesion;
  11. Significant (> 50%) in-stent restenoses proximal or distal to the target lesion that might require revascularization or impede runoff;
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00231257

Locations
United States, Minnesota
Mayo Clinic Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Cordis Corporation
Investigators
Principal Investigator: David R. Holmes, Jr., MD Mayo Clinic Rochester, Minnesota
  More Information

Publications:
Responsible Party: David R. Holmes, Jr., MD, Mayo Clinic Rochester, Minnesota
ClinicalTrials.gov Identifier: NCT00231257     History of Changes
Other Study ID Numbers: P02-6313
Study First Received: September 30, 2005
Last Updated: November 17, 2009
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Sirolimus
Everolimus
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Antifungal Agents
Anti-Infective Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Anti-Bacterial Agents

ClinicalTrials.gov processed this record on April 17, 2014